Abderrahmane Laadem

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes

Pierre Fenaux, Uwe Platzbecker, Ghulam J. Mufti et al. · New England Journal of Medicine · 2020 · 519 citations · Full text

A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia

Maria Domenica Cappellini, Vip Viprakasit, Alì Taher et al. · New England Journal of Medicine · 2020 · 289 citations

Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

Uwe Platzbecker, Ulrich Germing, Katharina S. Götze et al. · The Lancet Oncology · 2017 · 286 citations

Dose-finding Study, Hematological Malignancy, Hematology +6

Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study

Jörge E. Cortes, Joseph O. Moore, Richard T. Maziarz et al. · Journal of Clinical Oncology · 2010 · 193 citations · Full text

Sotatercept in patients with osteolytic lesions of multiple myeloma

Abdulkadyrov Km, Galina Salogub, Nuriet K. Khuazheva et al. · British Journal of Haematology · 2014 · 123 citations · Full text

Hematological Malignancy, Therapeutic Drug Monitoring, Sclerostin +14